Genelux (GNLX) Non-Current Debt (2022)
Genelux's (GNLX) quarterly Non-Current Debt came in at $1.1 million in Q4 2022.
Genelux (GNLX) Non-Current Debt (2022) Analysis & Trends
Genelux's Non-Current Debt history runs 1 years deep, the most recent figure standing at $1.1 million for Q4 2022.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $1.1 million in Q4 2022; TTM through Dec 2022 was $1.1 million, a N/A change from a year earlier, with the FY2022 full-year figure at $1.1 million, changed N/A from the prior year.
- Non-Current Debt steadied at $1.1 million in Q4 2022 per GNLX's latest filing.
- Across five years, Non-Current Debt topped out at $1.1 million in Q4 2022 and bottomed at $1.1 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.10 Mn |